Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Class A Common Stock
-
Shares outstanding
-
60.6M
-
Number of holders
-
32
-
Total 13F shares, excl. options
-
11.7M
-
Shares change
-
-362K
-
Total reported value, excl. options
-
$56.9M
-
Value change
-
-$4.4M
-
Number of buys
-
14
-
Number of sells
-
-15
-
Price
-
$4.85
Significant Holders of Immuneering Corp - Class A Common Stock (IMRX) as of Q4 2022
36 filings reported holding IMRX - Immuneering Corp - Class A Common Stock as of Q4 2022.
Immuneering Corp - Class A Common Stock (IMRX) has 32 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 11.7M shares
of 60.6M outstanding shares and own 19.34% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (3.62M shares), Cormorant Asset Management, LP (2.29M shares), CITADEL ADVISORS LLC (2.14M shares), BlackRock Inc. (1.35M shares), VANGUARD GROUP INC (838K shares), T. Rowe Price Investment Management, Inc. (458K shares), GEODE CAPITAL MANAGEMENT, LLC (169K shares), FMR LLC (153K shares), TD Asset Management Inc (147K shares), and MANUFACTURERS LIFE INSURANCE COMPANY, THE (82.5K shares).
This table shows the top 32 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.